Immune Checkpoint Inhibitors

Preferred Label : Immune Checkpoint Inhibitors;

MeSH definition : Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies.;

MeSH synonym : Checkpoint Inhibitors, Immune; Immune Checkpoint Inhibitor; Checkpoint Inhibitor, Immune; Immune Checkpoint Blockers; Checkpoint Blockers, Immune;

MeSH Hyperonym : Checkpoint Blockade, Immune; Immune Checkpoint Inhibition; Checkpoint Inhibition, Immune;

MeSH hyponym : PD L1 Inhibitors; PD-L1 Inhibitor; PD L1 Inhibitor; Programmed Death-Ligand 1 Inhibitors; Programmed Death Ligand 1 Inhibitors; CTLA 4 Inhibitors; CTLA-4 Inhibitor; CTLA 4 Inhibitor; Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors; Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors; Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor; Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor; PD 1 Inhibitors; PD-1 Inhibitor; Inhibitor, PD-1; PD 1 Inhibitor; Programmed Cell Death Protein 1 Inhibitor; Programmed Cell Death Protein 1 Inhibitors; Blockade, PD-1-PD-L1; PD 1 PD L1 Blockade;

Wikipedia link : https://en.wikipedia.org/wiki/Immune checkpoint inhibitor;

Details

Origin ID

D000082082;

UMLS CUI

C4684977;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Cytotoxic T-lymphocyte-associated protein 4 inhibitor (disposition) [SNOMED CT concept]
- Immune checkpoint inhibitor (disposition) [SNOMED CT concept]
- PD-L1 Inhibitor [NCIt concept]
- PD1 Inhibitor [NCIt concept]
- Programmed cell death protein 1 inhibitor (disposition) [SNOMED CT concept]
- Substance with cytotoxic T-lymphocyte-associated protein 4 inhibitor mechanism of action (substance) [SNOMED CT concept]
- Substance with immune checkpoint inhibitor mechanism of action (substance) [SNOMED CT concept]
- Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Immune Checkpoint Inhibitor [NCIt concept]
MeSH Descriptor(s) used for indexing
- Immune Checkpoint Proteins [MeSH Descriptor]
Record concept(s)
- CTLA-4 Inhibitors [MeSH concept]
- Immune Checkpoint Blockade [MeSH concept]
- Immune Checkpoint Inhibitors [MeSH concept]
- PD-1 Inhibitors [MeSH concept]
- PD-1-PD-L1 Blockade [MeSH concept]
- PD-L1 Inhibitors [MeSH concept]
See also inter- (CISMeF)
- immune checkpoint inhibitor-induced colitis [SYNODOS term]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- Abatacept [MeSH Descriptor]
- Ipilimumab [MeSH Descriptor]
- Nivolumab [MeSH Descriptor]
- Opdualag [MeSH Supplementary Concept]
- PHI-101 [MeSH Supplementary Concept]
- atezolizumab [MeSH Supplementary Concept]
- lisavanbulin [MeSH Supplementary Concept]
- pembrolizumab [MeSH Supplementary Concept]
- quemliclustat [MeSH Supplementary Concept]
- relatlimab [MeSH Supplementary Concept]
- sotorasib [MeSH Supplementary Concept]
- spartalizumab [MeSH Supplementary Concept]
- toripalimab [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Immune Checkpoint Inhibitor [NCIt concept]
- Immune checkpoint inhibitor (disposition) [SNOMED CT concept]
- Substance with immune checkpoint inhibitor mechanism of action (substance) [SNOMED CT concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients